Skip to main content
Premium Trial:

Request an Annual Quote

Roche to Help Simulations Plus Develop Drug Interaction Software

NEW YORK (GenomeWeb News) – Simulations Plus said today that it has signed a multi-year collaboration pact with Hoffmann La Roche, under which the pharmaceutical firm will provide funding and feedback in developing the firm’s GastroPlus software program for drug-drug interaction studies.
 
Lancaster, Calif.-based Simulations Plus said Roche would provide funding for the equivalent of one full-time scientist for two years.
 
“This collaboration will accelerate the implementation of what we expect to be the most advanced drug-drug interaction capability in the industry,” Viera Lukacova, Simulation Plus’ product manager for GastroPlus, said in a statement. “We’re especially pleased to have Roche scientists involved in this effort, as they have provided invaluable feedback and guidance to the implementation of our PBPK (physiologically based pharmacokinetics) capability in GastroPlus.”
 

The firm did not disclose terms of the collaboration.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.